



THE PLATFORM GROUP

Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

The Platform Group AG raises its forecast for 2026 to EUR 1 billion in sales and EUR 70-80 million in EBITDA - three acquisitions in the pharmaceutical sector and expansion in the Optics & Hearing segment

Düsseldorf, 2 October 2025. The Management Board of The Platform Group AG (ISIN: DE000A2QEFA1) has decided to raise its medium-term forecast for the 2026 financial year. Net sales of around EUR 1.0 billion (previous forecast: over EUR 860 million) and adjusted EBITDA in a range of EUR 70 million to EUR 80 million (previous forecast: over EUR 64 million) are now expected. Gross merchandise volume (GMV) is expected to rise to around EUR 1.7 billion (previous forecast: EUR 1.6 billion). The forecast for the 2025 financial year remains unchanged.

The rationale behind the raise are three majority acquisitions in the pharmaceutical sector, which were signed in September and October 2025. The three companies are the Vienna-based Pharmosan Group, the Brno-based Vamida mail-order pharmacy, and the Cologne-based pharmaceutical training platform Apothekia. Together, the three companies represent an expected sales volume of over EUR 130 million in 2026. The "Service & Retail Goods" segment will be expanded as a result and will be renamed "Pharma & Service Goods" in the future. The transactions are expected to close by the end of 2025, subject to approval by the relevant antitrust authorities.

In addition, The Platform Group has entered into agreements to acquire two further companies in the "Optics & Hearing" segment. Together, these companies generate sales in the single-digit million range with an EBITDA margin of around 24%.

Contact:

Investor Relations

Nathalie Richert

Head of Investor Relations

ir@the-platform-group.com

Schloss Elbroich | Am Falder 4 | 40589 Düsseldorf | Germany

corporate.the-platform-group.com